Inhibrx Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Inhibrx Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Inhibrx Biosciences: 6 sponsored US clinical trials, 2 recruiting.

Inhibrx Biosciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Conventional Chondrosarcoma, with 1 trials.

Upper-quartile sponsor footprint

Inhibrx Biosciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 2

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731
RECRUITING Phase 1

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933
ACTIVE NOT RECRUITING Phase 2

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075
ACTIVE NOT RECRUITING Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
COMPLETED Phase 1

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

NCT03815396
TERMINATED Phase 1

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Therapeutic Areas

Conventional Chondrosarcoma 1
Head and Neck Squamous Cell Carcinoma (HNSCC) 1
Ewing Sarcoma 1
Gastric Cancer 1
Melanoma 1
Renal Cell Carcinoma 1
Non-Small Cell Lung Cancer 1
Solid Tumor 1
Urothelial Carcinoma 1
Head and Neck Cancer 1

What is open in the Inhibrx Biosciences pipeline

2 recruiting of 6 indexed (33% open); 1 completed (17%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Conventional Chondrosarcoma (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Inhibrx Biosciences: open-pipeline peers nationwide

Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Inhibrx Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%20%40%60%80% Total trials Recruiting share Inhibrx Biosciences23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Inhibrx Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Inhibrx Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Inhibrx Biosciences page

6 registered trials is a research-attention snapshot, not an endorsement of Inhibrx Biosciences or any single study.

  • 2 of Inhibrx Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Conventional Chondrosarcoma is the condition Inhibrx Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Conventional Chondrosarcoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Inhibrx Biosciences pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.